Bausch Health Companies Inc. Deferred Tax Liabilities, Unrealized Currency Transaction Gains
Bausch Health Companies Inc. (BHC) had Deferred Tax Liabilities, Unrealized Currency Transaction Gains of $0 as of 2021-12-31, per its 8-K filed 2022-05-11.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains · last filed 2022-05-11
- 2021-12-31: Deferred Tax Liabilities, Unrealized Currency Transaction Gains $0.00.
- 2020-12-31: Deferred Tax Liabilities, Unrealized Currency Transaction Gains $2.00M.
- 2019-12-31: Deferred Tax Liabilities, Unrealized Currency Transaction Gains $0.00.
| Period end | Deferred Tax Liabilities, Unrealized Currency Transaction Gains |
|---|---|
| 2021-12-31 | $0.00 8-K · filed 2022-05-11 |
| 2020-12-31 | $2.00M 8-K · filed 2022-05-11 |
| 2019-12-31 | $0.00 8-K · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |